<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIAZOLAM</span><br/>(trye-ay'zoe-lam)<br/><span class="topboxtradename">Halcion<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">benzodiazepine</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span><br/><b>Prototype: </b>Lorazepam<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.125 mg, 0.25 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Benzodiazepine derivative with hypnotic effects with fewer residual daytime effects. Its blockade of cortical and limbic arousal
         results in hypnotic activity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Drug-induced effects on sleep include decreased sleep latency and number of nocturnal awakenings, decreased total nocturnal
         wake time, and increased duration of sleep.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of insomnia characterized by difficulty in falling asleep, frequent wakeful periods. Following long-term
         use, tolerance or adaptation may develop.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to triazolam and benzodiazepines; pregnancy (category X), lactation; concurrent administration with the following
         medications which impair cytochrome P450 3A (e.g. ketoconazole, itraconazole, and nefazodone.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Depression; older adults and debilitated patients; patients with suicidal tendency; impaired kidney or liver function; chronic
         pulmonary insufficiency; sleep apnea.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Insomnia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.1250.25 mg h.s. (max: 0.5 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 0.06250.125 mg h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give immediately before bed; onset of drug action is rapid.</li>
<li>Do not exceed recommended doses.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> light-headedness, headache, dizziness, ataxia, visual disturbances, confusional states, <span class="speceff-common">memory impairment, "rebound insomnia," anterograde amnesia,</span> paradoxical reactions, minor changes in EEG patterns. <span class="typehead">GI:</span> Nausea, vomiting, constipation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b>, <span class="classification">cns depressants</span>, <span class="classification">anticonvulsants</span>, <b>nefazodone,</b>
<span class="classification">benzodiazepines</span> potentiate CNS depression; <b>cimetidine</b> increases triazolam plasma levels, thus increasing its toxicity; may decrease antiparkinsonism effects of <b>levodopa.</b> <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 1530 min. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 68 h.  <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolites. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be aware that signs of developing tolerance or adaptation (with long-term use) include increased daytime anxiety, increased
            wakefulness during last one third of the night.
         </li>
<li>Lab tests: Obtain periodic blood counts, urinalysis, and blood chemistries during long-term use.</li>
<li>Do not use with addiction-prone patients (drug addicts, alcoholics) unless careful surveillance by health personnel is available.
            Habituation and dependence can occur.
         </li>
<li>Evaluate smoking habit. As with other benzodiazepines, smoking may decrease hypnotic effects.</li>
<li>Monitor for symptoms of overdosage: Slurred speech, somnolence, confusion, impaired coordination, and coma.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Avoid use of alcohol or other CNS depressants while on this drug; they may increase sedative effects.</li>
<li>Do not stop taking drug suddenly, especially if you are subject to seizures. Withdrawal symptoms may occur and range from
            mild dysphoria to more serious symptoms (e.g., tremors, abdominal and muscle cramps, convulsions). Consult physician for schedule
            to discontinue therapy.
         </li>
<li>Do not increase dose without physician's advice because of toxic potential of drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>